Assessment and Appraisal of Drug Innovativeness in Italy: Ultimate Evidence on Key Drivers and Consistency
Alvise Verde, Federica Turati, Clara Trimarchi, Carlotta Galeone, Claudio Jommi · 2026
Read Assessment and Appraisal of Drug Innovativeness in Italy: Ultimate Evidence on Key Drivers and Consistency by Alvise Verde, Federica Turati, Clara Trimarchi, Carlotta Galeone, Claudio Jommi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13214850.txt.
Description
Verde and co-authors update proof on how Italy's drug agency judges whether new drugs count as innovative. Appraisals from July 2017 to December 2024 were pulled from the agency website. The team tested links between verdicts and graded domains such as unmet need.
Added therapeutic value tied most strongly to an innovative verdict, with odds over seventy. Rare disease drugs were more likely to get conditional status, at odds of 2 point 95. Full status came more often for uses that include children, at odds of 3 point 60. Indirect comparisons lowered the odds sharply, to 0 point 18. The study checks these patterns against the 2025 reform.
Catalog record
| CREATOR | Alvise Verde, Federica Turati, Clara Trimarchi, Carlotta Galeone, Claudio Jommi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |